Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.

Peixin ChenLiping ZhangWei ZhangChenglong SunChunyan WuYayi HeCai-Cun Zhou

Published in: Journal for immunotherapy of cancer (2021)

Gal-9 is markedly related to tumor-immune microenvironment and immune infiltration in SCLC. This study emphasized the predictive value and promising clinical applications of Gal-9 in stage I-III SCLC.

Keyphrases

small cell lung cancer
stem cells
brain metastases
free survival
drug induced